LMR Partners’s AbCellera Biologics ABCL Stock Holding History

LMR Partners’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-25,236	Closed	-$116K	–	974
2023 Q3	$116K	Hold	25,236	–	–	﹤0.01%	670
2023 Q2	$163K	Buy	+25,236	New	+$172K	﹤0.01%	595

Other funds holding ABCL

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FFVM

Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

LMR Partners's ABCL Position: Q4 2023 in Review

LMR Partners sold out of AbCellera Biologics (ABCL) in Q4 2023, closing a stake of 25,236 shares — an estimated $116K sold.

LMR Partners first reported a position in ABCL in Q2 2023 and held it in 2 quarters. The position peaked at $163K in Q2 2023. 142 funds tracked by Wall St. Rank hold ABCL as of Q4 2023.

LMR Partners reported no remaining AbCellera Biologics position as of Q4 2023 after selling out during the quarter.
LMR Partners sold 25,236 AbCellera Biologics shares in Q4 2023, an estimated $116K.
LMR Partners first reported a position in AbCellera Biologics in Q2 2023 and held it in 2 quarters.
LMR Partners's AbCellera Biologics position peaked at $163K in Q2 2023.
142 funds tracked by Wall St. Rank held AbCellera Biologics as of Q4 2023.

Based on LMR Partners's 13F filing for Q4 2023, filed 14 Feb 2024.